Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sranan Acquires Lawantino Gold Project Along the Prolific Antino-Sela Creek Trend (click to learn more) This AI Wellness Platform Is Scaling Fast (click to learn more) A Closer Look at Cannabis Company HERB (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

Healthcare Biotechnology
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company’s products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety disorder, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat anxiety related disorders, including benzodiazepine dependency. It is also developing MM-001, a topical cream formulation of interferon-alpha 2b, which has completed Phase II clinical trials for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation that has completed Phase II clinical trials for the treatment of COVID-19 and other...


CSE:BETR - Post by User

BetterLife Pharma Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(564)
•••
  • rixpixX
Post by rixpixon Jun 27, 2024 11:05am
138 Views
Post# 36108903

Fair value for BETR is 100% higher than here

Fair value for BETR is 100% higher than hereAccording to MorningStar's rating, BETR is valued @ 26 cents.

That's more than double what the shares are trading at right now.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities